<i>LMNA</i> Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

<i>LMNA</i> Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually dev...

Full description

Bibliographic Details
Main Authors: Chunsheng Hu, Anting Zhou, Xin Hu, Yu Xiang, Mengjun Huang, Jiuhong Huang, Donglin Yang, Yan Tang
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:International Journal of Molecular Sciences
Subjects:
<i>LMNA</i>
epithelial–mesenchymal transition
EGFR-TKI resistance
non-small-cell lung cancer
Online Access:https://www.mdpi.com/1422-0067/23/21/13237

Internet

https://www.mdpi.com/1422-0067/23/21/13237

Similar Items